-transparent.png){kind=logo}
Recombinant human single-chain urokinase (rscu-PA), two-chain urokinase (tcu-PA), and diisopropyl-fluorophosphate-treated tcu-PA (DFP-tcu-PA) bound to cultured human and porcine endothelial cells in a rapid, saturable, dose-dependent and reversible manner. Analysis of specific binding results in cultured human umbilical vein endothelial cells (HUVECs) gave the following estimated values for Kd and Bmax: 0.57 +/- 0.08 nM (mean +/- S.E.) and 188,000 +/- 18,000 sites/cell for 125I-labeled rscu-PA; 0.54 +/- 0.10 nM and 132,000 +/- 23,900 sites/cells for 125I-labeled tcu-PA; 0.89 +/- 0.14 nM and 143,000 +/- 30,300 sites/cell for 125I-labeled DFP-tcu-PA, respectively. Values for Kd were similar for primary and subcultured (six passages) HUVECs, but Bmax values were lower in subcultured HUVECs. Similar Kd values were found in cultured porcine endothelial cells; however, Bmax values varied depending on the endothelial cell type. All 125I-labeled urokinase forms yielded similar cross-linked approximately 110-kDa ligand-receptor complexes with cultured HUVECs, and 125I-labeled DFP-tcu-PA bound to a single major approximately 55-kDa protein in whole-cell lysates (ligand blotting/autoradiography), suggesting the presence of a single major approximately 55-kDa urokinase receptor in cultured HUVECs. The approximately 55-kDa urokinase receptor, isolated from several separate batches of cultured HUVECs (3-5 micrograms of protein, approximately 1 x 10(9) cells), by ligand affinity chromatography, exhibited the following properties: retained biologic activity as evidenced by its ability to bind 125I-labeled rscu-PA by ligand blotting/autoradiography and formation of a cross-linked 125I-labeled approximately 110-kDa rscu-PA-receptor complex; single-chain approximately 55-kDa protein, following reduction; complete conversion to and formation of a single major deglycosylated approximately 35-kDa protein, following treatment with N-glycanase.
R C Haddock, and
M L Spell, and
C D Baker, and
J R Grammer, and
J M Parks, and
M Speidel, and
F M Booyse
March 1995,
Arteriosclerosis, thrombosis, and vascular biology,
R C Haddock, and
M L Spell, and
C D Baker, and
J R Grammer, and
J M Parks, and
M Speidel, and
F M Booyse
April 2003,
FASEB journal : official publication of the Federation of American Societies for Experimental Biology,
R C Haddock, and
M L Spell, and
C D Baker, and
J R Grammer, and
J M Parks, and
M Speidel, and
F M Booyse
February 2001,
Alcoholism, clinical and experimental research,
R C Haddock, and
M L Spell, and
C D Baker, and
J R Grammer, and
J M Parks, and
M Speidel, and
F M Booyse
September 1985,
Experimental eye research,
R C Haddock, and
M L Spell, and
C D Baker, and
J R Grammer, and
J M Parks, and
M Speidel, and
F M Booyse
May 1996,
Experimental cell research,
R C Haddock, and
M L Spell, and
C D Baker, and
J R Grammer, and
J M Parks, and
M Speidel, and
F M Booyse
March 1997,
Molecular and cellular biology,
R C Haddock, and
M L Spell, and
C D Baker, and
J R Grammer, and
J M Parks, and
M Speidel, and
F M Booyse
June 1983,
Cell biology international reports,
R C Haddock, and
M L Spell, and
C D Baker, and
J R Grammer, and
J M Parks, and
M Speidel, and
F M Booyse
April 1995,
The Journal of biological chemistry,
R C Haddock, and
M L Spell, and
C D Baker, and
J R Grammer, and
J M Parks, and
M Speidel, and
F M Booyse
September 1982,
The Journal of cell biology,
R C Haddock, and
M L Spell, and
C D Baker, and
J R Grammer, and
J M Parks, and
M Speidel, and
F M Booyse
February 1994,
Journal of neurochemistry,
